Gliever-M2 Tablet SR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, formulated for sustained release to provide effective glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. The sustained-release formulation ensures a gradual release of active ingredients, promoting better tolerability and adherence by minimizing gastrointestinal side effects commonly associated with Metformin immediate-release formulations. Gliever-M2 is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or lifestyle modification alone. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Contraindications include patients with severe renal impairment, metabolic acidosis, or hypersensitivity to any component. Caution is advised in patients with hepatic dysfunction, cardiovascular disease, or during periods of acute illness. Gliever-M2 should be used under medical supervision, with periodic assessment of renal function and blood glucose to optimize treatment outcomes and minimize adverse effects.